Mitsui & Co. Global Investment (MGI) - Venture Capital, Start-Up

NEWS 2007

[10/25/2007]

DiObex Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that Keith A. Vendola, MD, Head of Corporate Development, will deliver a corporate presentation at the upcoming Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York, New York. The DiObex presentation will take place on Monday, November 5 at 4:25 p.m. at the New York Palace Hotel in the Hubbard Room.

About DiObex

DiObex, Inc. is a San Francisco-based biopharmaceutical company founded to develop novel products for the treatment of metabolic diseases. DiObex has two products preparing to enter Phase 2b clinical development. DIO-901 is a formulation of Very Low Dose Glucagon (VLD Glucagon) for reducing or preventing insulin induced hypoglycemia. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 is a single enantiomer of ketoconazole and is a novel cortisol synthesis inhibitor. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type-2 diabetes and cardiovascular disease. For more information, visit www.diobex.com.

Contact:

Keith Vendola
DiObex
(415) 551-4115
keith@diobex.com